Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 3, Mars 2011
Page(s) 297 - 302
Section M/S revues
DOI https://doi.org/10.1051/medsci/2011273297
Publié en ligne 30 mars 2011
  1. DominiciM, Le BlancK, MuellerI, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006 ; 8 : 315-317. [CrossRef] [PubMed]
  2. CrisanM, YapS, CasteillaL, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008 ; 3 : 301-313. [CrossRef] [PubMed]
  3. SensebéL, BourinP. Producing MSC according GMP: process and controls. Biomed Mater Eng 2008 ; 18 : 173-177. [PubMed]
  4. BaxterMA, WynnRF, JowittSN, et al. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004 ; 22 : 675-682. [CrossRef] [PubMed]
  5. StolzingA, JonesE, McGonagleD, ScuttA. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008 ; 129 : 163-173. [CrossRef] [PubMed]
  6. KernS, EichlerH, StoeveJ, et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006 ; 24 : 1294-1301. [CrossRef] [PubMed]
  7. BiebackK, KernS, KlüterH, EichlerH. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004 ; 22 : 625-634. [CrossRef] [PubMed]
  8. GronthosS, ZannettinoACW, HaySJ, et al. Molecular and cellular characterisation of highly purified stromal cells derived from human bone marrow. Cell Sci 2003 ; 116 : 1827-1835. [CrossRef] [PubMed]
  9. QuiriciN, SoligoD, BossolascoP, et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002 ; 30 : 783-791. [CrossRef] [PubMed]
  10. DeschaseauxF, CharbordP. Human marrow stromal precursors are alpha 1 integrin subunit-positive. Cell Physiol 2000 ; 184 : 319-325. [CrossRef]
  11. KoçON, GersonSL, CooperBW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultured-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Clin Oncol 2000 ; 18 : 307-316.
  12. ColterDC, SekiyaI, ProckopDJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001 ; 98 : 7841-7845. [CrossRef]
  13. SekiyaI, LarsonBJ, SmithJR, et al. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002 ; 20 : 530-541. [CrossRef] [PubMed]
  14. BanfiA, MuragliaA, DozinB, et al. Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol 2000 ; 28 : 707-715. [CrossRef] [PubMed]
  15. MuragliaA, CanceddaR, QuartoR. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. Cell Sci 2000 ; 113 : 1161-1166.
  16. NgF, BoucherS, KohS, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008 ; 112 : 295-307. [CrossRef] [PubMed]
  17. MüllerI, KordowichS, HolzwarthC, et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006 ; 8 : 437-444. [CrossRef] [PubMed]
  18. KocaoemerA, KernS, KlüterH, BiebackK. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007 ; 25 : 1270-1278. [CrossRef] [PubMed]
  19. ChaseLG, LakshmipathyU, SolchagaLA, et al. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010 ; 1 : 8. [CrossRef] [PubMed]
  20. TarteK, GaillardJ, LatailladeJJ, et al. Société française de greffe de moelle et thérapie cellulaire. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010 ; 115 : 1549-1553. [CrossRef] [PubMed]
  21. GodaraP, McFarlandCD, NordonRE. Design of bioreactors for mesenchymal stem cell tissue engineering. Chem Technol Biotechnol 2010 ; 83 : 408-420.
  22. SerakinciN, GuldbergP, BurnsJS, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004 ; 23 : 5095-5098. [CrossRef] [PubMed]
  23. RubioD, Garcia-CastroJ, MartınMC, et al. Spontaneous human adult stem cell transformation. Cancer Res 2005 ; 65 : 3035-3039. [PubMed]
  24. RoslandGV, SvendsenA, TorsvikA, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009 ; 69 : 5331-5339. [CrossRef] [PubMed]
  25. GarciaS, MartinMC, de la FuenteR, et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res 2010 ; 316 : 1648-1650. [CrossRef] [PubMed]
  26. TorsvikA, RoslandGV, SvendsenA, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track. Cancer Res 2010 ; 70 : 6393-6396. [CrossRef] [PubMed]
  27. HayflickL. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1963 ; 37 : 614-636. [CrossRef] [PubMed]
  28. CampisiJ, d’Adda di FagagnaF. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007 ; 8 : 729-740. [CrossRef] [PubMed]
  29. CoppéJP, PatilCK, RodierF, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PloS Biol 2008 ; 12 : 2853-2868.
  30. DjouadF, PlenceP, BonyC, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003 ; 102 : 3837-3844. [CrossRef] [PubMed]
  31. HoughtonJM, LiH, FanX, et al. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cell Dev 2010 ; 19 : 1153-1166. [CrossRef]
  32. WagnerW, HornP, CastoldiM, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PloS One 2008 ; 3 : 1-12. [PubMed]
  33. ProckopDJ, BrennerM, FibbeWE, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010 ; 12 : 576-578. [CrossRef] [PubMed]
  34. BischofO, DejeanA, PineauP. Une revue de la sénescence cellulaire : ami ou ennemi de la promotion tumorale ?Med Sci (Paris) 2009 ; 25 : 153-160. [CrossRef] [EDP Sciences] [PubMed]
  35. CharbordP, CasteillaL. La biologie des cellules souches mésenchymateuses d’origine humaine. Med Sci (Paris) 2011 ; 27 : 261-268. [CrossRef] [EDP Sciences] [PubMed]
  36. LazennecG. Les cellules souches mésenchymateuses : armes ou dangers pour le traitement des cancers ?Med Sci (Paris) 2011 ; 27 : 285-288. [CrossRef] [EDP Sciences] [PubMed]
  37. JorgensenC, DeschaseauxF, Planat-BenardV, GabisonE. Les cellules souches mésenchymateuses : actualités thérapeutiques. Med Sci (Paris) 2011 ; 27 : 275-284. [CrossRef] [EDP Sciences] [PubMed]
  38. VinatierC, BordenaveL, GuicheuxJ, AmédéeJ. Les cellules souches en ingénierie des tissus ostéoarticulaires et vasculaires. Med Sci (Paris) 2011 ; 27 : 289-296. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.